Related Experiment Video
Updated: Aug 8, 2026
Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
Heparan sulfate binding protein treatment ameliorates neuropathology and behavioral abnormalities in
Serenella Anzilotti1, Melania Scarcella2, Mariangela Ciampa2
1Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy.
Abstract:
Mucopolysaccharidosis IIIB (MPS IIIB) is a metabolic neurodegenerative disorder caused by a deficiency of the lysosomal enzyme α-N-acetylglucosaminidase (NAGLU), which is involved in the degradation of heparan sulfate (HS). Affected patients exhibit progressive neurodegeneration, behavioral disturbances, and a shortened lifespan. Currently, there is no effective treatment for MPS IIIB. We have recently developed a new therapeutic strategy based on the use of the HS-binding protein NK1, a spliced variant of hepatocyte growth factor. Here, we demonstrate that treating Naglu-/- mice with recombinant NK1 ameliorates neuropathology by reducing HS storage, lysosomal dysfunction, autophagy imbalance, and neuroinflammation in the cortex and hippocampus of MPS IIIB mouse brains. Furthermore, we found that recombinant NK1 treatment improves cognitive behavior and motor activity in Naglu-/- mice, as assessed using open field, object recognition, and T-maze tests. Our findings suggest that recombinant NK1 is a promising candidate for the treatment of MPS IIIB and other lysosomal storage diseases associated with central nervous system dysfunction.
Insights
Mucopolysaccharidosis IIIB (MPS IIIB) is a rare neurodegenerative disease. Recombinant NK1 protein shows promise in treating MPS IIIB by reducing brain pathology and improving behavior in mouse models.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Mucopolysaccharidosis IIIB (MPS IIIB) is a lysosomal storage disease caused by NAGLU deficiency, leading to heparan sulfate accumulation and neurodegeneration.
- Current treatments for MPS IIIB are lacking, necessitating the development of novel therapeutic strategies.
- Heparan sulfate (HS) accumulation disrupts cellular functions, contributing to the progressive neurological decline observed in MPS IIIB patients.
Purpose of the Study:
- To evaluate the therapeutic potential of recombinant NK1 protein in a mouse model of MPS IIIB.
- To investigate the effects of NK1 on HS storage, lysosomal dysfunction, autophagy, and neuroinflammation in the MPS IIIB brain.
- To assess the impact of NK1 treatment on cognitive and motor functions in MPS IIIB mice.
Main Methods:
- Treatment of Naglu-/- mice (MPS IIIB model) with recombinant NK1 protein.
- Histopathological analysis of brain tissue to assess HS storage, lysosomal markers, and neuroinflammation.
- Behavioral testing including open field, object recognition, and T-maze tests to evaluate cognitive and motor functions.
Main Results:
- Recombinant NK1 treatment significantly reduced HS storage in the cortex and hippocampus of Naglu-/- mice.
- NK1 administration ameliorated lysosomal dysfunction, autophagy imbalance, and neuroinflammation in the MPS IIIB mouse brain.
- Cognitive behavior and motor activity were notably improved in NK1-treated Naglu-/- mice.
Conclusions:
- Recombinant NK1 protein demonstrates significant therapeutic efficacy in ameliorating neuropathology and functional deficits in an MPS IIIB mouse model.
- NK1 treatment offers a promising therapeutic strategy for MPS IIIB by targeting key pathological mechanisms.
- These findings suggest NK1's potential application in treating other lysosomal storage diseases affecting the central nervous system.
More Related Videos
Related Concept Videos
01:22Lysosomal Hydrolases
01:23Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...